UA80841C2 - Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants) - Google Patents
Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants)Info
- Publication number
- UA80841C2 UA80841C2 UAA200504339A UA2005004339A UA80841C2 UA 80841 C2 UA80841 C2 UA 80841C2 UA A200504339 A UAA200504339 A UA A200504339A UA 2005004339 A UA2005004339 A UA 2005004339A UA 80841 C2 UA80841 C2 UA 80841C2
- Authority
- UA
- Ukraine
- Prior art keywords
- substituted
- unsubstituted
- variants
- disorders
- glaucoma
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- -1 biphenylyl Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000027559 Appetite disease Diseases 0.000 abstract 1
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 abstract 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 239000003940 fatty acid amidase inhibitor Substances 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/54—Y being a carbon atom of a six-membered aromatic ring, e.g. benzoylureas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41700802P | 2002-10-07 | 2002-10-07 | |
| PCT/US2003/031844 WO2004033422A2 (en) | 2002-10-07 | 2003-10-07 | Modulation of anxiety through blockade of anandamide hydrolysis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA80841C2 true UA80841C2 (en) | 2007-11-12 |
Family
ID=32093946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200504339A UA80841C2 (en) | 2002-10-07 | 2003-10-07 | Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants) |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7176201B2 (https=) |
| EP (1) | EP1558591B1 (https=) |
| JP (1) | JP4515911B2 (https=) |
| KR (1) | KR20050088992A (https=) |
| CN (1) | CN100408556C (https=) |
| AU (1) | AU2003279877B2 (https=) |
| CA (1) | CA2501506C (https=) |
| EA (1) | EA010267B1 (https=) |
| MX (1) | MXPA05003715A (https=) |
| UA (1) | UA80841C2 (https=) |
| WO (1) | WO2004033422A2 (https=) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9923738D0 (en) * | 1999-10-07 | 1999-12-08 | Nestle Sa | Nutritional composition |
| US20050054730A1 (en) * | 2001-03-27 | 2005-03-10 | The Regents Of The University Of California | Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha |
| CA2442330A1 (en) * | 2001-03-29 | 2002-10-10 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| WO2004034968A2 (en) * | 2002-08-20 | 2004-04-29 | The Regents Of The University Of California | Combination therapy for controlling appetites |
| EA010267B1 (ru) * | 2002-10-07 | 2008-06-30 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Модуляция тревоги через блокаду гидролиза анандамида |
| US20050026844A1 (en) * | 2003-04-03 | 2005-02-03 | Regents Of The University Of California | Inhibitors for the soluble epoxide hydrolase |
| WO2005089380A2 (en) | 2004-03-16 | 2005-09-29 | The Regents Of The University Of California | Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids |
| JP2007509066A (ja) * | 2003-10-16 | 2007-04-12 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 体脂肪を減らし、食欲を抑制し、脂肪酸代謝を調節するための食物および他の組成物、化合物ならびに方法 |
| FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866886B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique |
| PL1761480T3 (pl) * | 2004-06-23 | 2009-07-31 | Hoffmann La Roche | Inhibitory mao-b |
| US20060084659A1 (en) * | 2004-10-19 | 2006-04-20 | Michael Davis | Augmentation of psychotherapy with cannabinoid reuptake inhibitors |
| JP2008517072A (ja) * | 2004-10-20 | 2008-05-22 | ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 可溶性エポキシド加水分解酵素の改良された阻害剤 |
| KR100693528B1 (ko) * | 2004-10-29 | 2007-03-14 | 주식회사 팬택 | 전원 지연 인가 기능을 가지는 무선통신 단말기 |
| WO2006058088A2 (en) * | 2004-11-23 | 2006-06-01 | Ptc Therapeutics, Inc. | Carbazole, carboline and indole derivatives useful in the inhibition of vegf production |
| TWI385164B (zh) * | 2005-02-17 | 2013-02-11 | Astellas Pharma Inc | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (II) |
| WO2006116773A2 (en) * | 2005-04-28 | 2006-11-02 | The Regents Of The University Of California | Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders |
| EP1954137A4 (en) * | 2005-11-18 | 2008-12-17 | Janssen Pharmaceutica Nv | 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE |
| US20070155707A1 (en) * | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Ionizable inhibitors of fatty acid amide hydrolase |
| MX2008008529A (es) * | 2005-12-29 | 2008-09-26 | Organon Nv | Inhibidores de amida hidrolasa de acido graso. |
| WO2007106706A1 (en) * | 2006-03-10 | 2007-09-20 | Boehringer Ingelheim International Gmbh | Cyclic urea compounds as soluble epoxide hydrolase inhibitors effective for the treatment of cardiovascular disorders |
| WO2007140005A2 (en) * | 2006-05-26 | 2007-12-06 | Janssen Pharmaceutica N.V. | Oxazolyl piperidine modulators of fatty acid amide hydrolase |
| WO2008021625A2 (en) * | 2006-08-18 | 2008-02-21 | N.V. Organon | Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent |
| US7888394B2 (en) | 2006-08-21 | 2011-02-15 | N.V. Organon | Synthesis, polymorphs, and pharmaceutical formulation of FAAH inhibitors |
| US20110172230A1 (en) | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
| WO2008030752A2 (en) * | 2006-09-07 | 2008-03-13 | N.V. Organon | Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo |
| US20090099240A1 (en) * | 2006-10-02 | 2009-04-16 | N.V. Organon | Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity |
| CA2674359A1 (en) * | 2006-11-20 | 2008-05-29 | N.V. Organon | Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
| WO2008100977A2 (en) * | 2007-02-14 | 2008-08-21 | N.V. Organon | Carbamates therapeutic release agents as amidase inhibitors |
| DE102007022007A1 (de) * | 2007-05-08 | 2008-11-13 | Schebo Biotech Ag | Neuartike Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Prophylaxe und Therapie von ZNS-Erkrankungen und Diabetes |
| US8372823B2 (en) | 2007-05-25 | 2013-02-12 | The Scripps Research Institute | Tetracyclic inhibitors of fatty acid amide hydrolase |
| CA2689148A1 (en) * | 2007-05-31 | 2008-12-11 | The Scripps Research Institute | Tricyclic inhibitors of fatty acid amide hydrolase |
| US8207226B1 (en) | 2008-06-03 | 2012-06-26 | Alcon Research, Ltd. | Use of FAAH antagonists for treating dry eye and ocular pain |
| TWI434842B (zh) | 2008-07-14 | 2014-04-21 | Astellas Pharma Inc | Azole compounds |
| JPWO2010053120A1 (ja) | 2008-11-06 | 2012-04-05 | アステラス製薬株式会社 | カルバメート化合物又はその塩 |
| FR2938537B1 (fr) * | 2008-11-14 | 2012-10-26 | Sanofi Aventis | Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique. |
| MX342128B (es) * | 2008-12-24 | 2016-09-14 | Bial - Portela & C A S A | Compuestos farmaceuticos. |
| FR2941696B1 (fr) * | 2009-02-05 | 2011-04-15 | Sanofi Aventis | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| US8735406B2 (en) | 2009-09-09 | 2014-05-27 | Dainippon Sumitomo Pharma Co., Ltd. | 8-oxodihydropurine derivative |
| WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
| FR2955580A1 (fr) * | 2010-01-28 | 2011-07-29 | Sanofi Aventis | Derives de carbamate d'alkyl-heterocycles, leur preparation et leur application en therapeutique |
| CA2787476C (en) * | 2010-01-20 | 2017-07-11 | Sanofi | Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application |
| US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
| EP2593078B1 (en) | 2010-05-25 | 2016-11-30 | Symrise AG | Cyclohexyl carbamate compounds as active anti-cellulite ingredients |
| EP2389922A1 (en) | 2010-05-25 | 2011-11-30 | Symrise AG | Cyclohexyl carbamate compounds as anti-ageing actives |
| BR112012029961B1 (pt) * | 2010-05-25 | 2017-06-06 | Symrise Ag | compostos de carbamato de ciclo-hexila, seus usos, composições cosméticas e métodos cosméticos para clareamento da pele e/ou cabelo |
| US9187413B2 (en) | 2010-07-28 | 2015-11-17 | The Regents Of The University Of California | Peripherally restricted FAAH inhibitors |
| EP2433527B1 (en) * | 2010-09-28 | 2013-04-03 | Gruppo Cimbali S.p.A. | Improved automatic milk frothing wand |
| KR102079404B1 (ko) * | 2011-08-19 | 2020-02-19 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 메타-치환된 비페닐 말초 제한형 faah 억제제 |
| WO2014023325A1 (en) * | 2012-08-06 | 2014-02-13 | Fondazione Istituto Italiano Di Tecnologia | Multitarget faah and cox inhibitors and therapeutical uses thereof |
| ITMI20131180A1 (it) | 2013-07-15 | 2015-01-16 | Fond Istituto Italiano Di Tecnologia | O-alchil triazolil carbammati come inibitori di idrolasi delle ammidi degli acidi grassi (faah) |
| RU2693457C2 (ru) * | 2013-07-18 | 2019-07-03 | Фондацьоне Иституто Итальяно Ди Текнолоджия | Фенилкарбаматы и их применения в качестве ингибиторов фермента гидролазы амидов жирных кислот (faah) и модуляторов d3 допаминового рецептора (d3dr) |
| AR100387A1 (es) * | 2014-02-18 | 2016-10-05 | Basf Se | Copolímeros que comprenden etileno, ésteres de vinilo y ésteres de ácido (met)acrílico, sus formulaciones y usos como depresor del punto de fluidez, inhibidor de cera y potenciador de flujo para petróleos crudos |
| ES2908240T3 (es) | 2014-04-07 | 2022-04-28 | Univ California | Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos |
| WO2016196879A1 (en) * | 2015-06-05 | 2016-12-08 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
| EP3381995B1 (en) | 2015-12-11 | 2019-10-23 | National University Corporation Shizuoka University | Oil-gelling agent |
| US10220061B1 (en) | 2017-09-26 | 2019-03-05 | Cynthia Denapoli | Method of reducing stress and anxiety in equines |
| EP3762034B1 (en) | 2018-03-05 | 2025-08-27 | Wylder Nation Foundation | A fatty acid amide hydrolase (faahi) inhibitor for use in inhibiting the cellular accumulation of a sphingolipid in a subject that has lysosomal storage disease or disorder |
| US10414721B1 (en) | 2018-06-04 | 2019-09-17 | University Of Bern | Inhibitor of endocannabinoid cellular reuptake |
| US20240180905A1 (en) * | 2020-07-21 | 2024-06-06 | Neuritek Ltd. | Uses of fatty acid amide hydrolase inhibitors in treatment of trauma related psychiatric disorders |
| WO2025015420A1 (en) * | 2023-07-17 | 2025-01-23 | Apogee Pharmaceuticals, Inc. | Novel fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE531554A (https=) * | 1953-09-02 | |||
| US3084096A (en) * | 1955-08-29 | 1963-04-02 | Union Carbide Corp | Indanyl n-methyl carbamate |
| US3275512A (en) * | 1962-11-27 | 1966-09-27 | Upjohn Co | Process for treating inflammation with biphenylcarbamates |
| US3632631A (en) * | 1967-09-08 | 1972-01-04 | Ethyl Corp | Sterically hindered bisphenyl carbamates |
| US3880908A (en) * | 1972-01-24 | 1975-04-29 | Standard Oil Co | Urethane derivatives of polymethyl biphenyl useful as fungicides |
| DE2943480A1 (de) | 1979-10-27 | 1981-05-07 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von n,o-disubstituierten urethanen, sowie ihre verwendung als ausgangsmaterial zur herstellung von isocyanaten |
| HU197831B (en) | 1984-12-20 | 1989-06-28 | Chinoin Gyogyszer Es Vegyeszet | Insecticide compositions containing alkenyl-oxy-phenyl-carbamat derivatives as active components and process for producing the active components |
| IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
| JPS63303661A (ja) | 1987-01-22 | 1988-12-12 | Ishikawajima Harima Heavy Ind Co Ltd | 注湯装置 |
| US4987233A (en) | 1988-06-15 | 1991-01-22 | Eli Lilly And Company | Process for preparing herbicidal ureas and insecticidal carbamates and carbamate derivatives |
| IL95994A0 (en) | 1989-11-15 | 1991-07-18 | American Home Prod | Carbamate esters and pharmaceutical compositions containing them |
| US5112859A (en) * | 1990-09-14 | 1992-05-12 | American Home Products Corporation | Biphenyl amide cholesterol ester hydrolase inhibitors |
| US5476944A (en) * | 1991-11-18 | 1995-12-19 | G. D. Searle & Co. | Derivatives of cyclic phenolic thioethers |
| US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| DE69314148T2 (de) | 1992-12-17 | 1998-01-15 | Valeo Systemes Essuyage | Stromversorgungsverfahren und -vorrichtung für einen elektrischen Motor zum Antrieb eines Scheibenwischers eines Kraftfahrzeugs |
| US5576220A (en) | 1993-02-19 | 1996-11-19 | Arris Pharmaceutical Corporation | Thin film HPMP matrix systems and methods for constructing and displaying ligands |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
| US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
| IT1271679B (it) | 1994-07-18 | 1997-06-04 | Mediolanum Farmaceutici Srl | Derivati del fenilcarbammato atti all'impiego come anticolinesterasici |
| DE4430600A1 (de) | 1994-08-22 | 1996-02-29 | Hoechst Schering Agrevo Gmbh | Biphenyl-Derivate |
| JPH0892167A (ja) * | 1994-09-21 | 1996-04-09 | Idemitsu Kosan Co Ltd | 芳香族炭酸ジエステルの製造方法 |
| US5585492A (en) * | 1994-10-11 | 1996-12-17 | G. D. Searle & Co. | LTA4 Hydrolase inhibitors |
| US6271015B1 (en) * | 1995-06-12 | 2001-08-07 | The Scripps Research Institute | Fatty-acid amide hydrolase |
| CA2206192A1 (en) * | 1996-06-13 | 1997-12-13 | F. Hoffmann-La Roche Ag | Modulation of lc132 (opioid-like) receptor function |
| US5856537A (en) * | 1996-06-26 | 1999-01-05 | The Scripps Research Institute | Inhibitors of oleamide hydrolase |
| US6150415A (en) | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
| US6531506B1 (en) * | 1996-08-13 | 2003-03-11 | Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of hypertension |
| SI20018A (sl) | 1996-11-19 | 2000-02-29 | Icn Pharmaceuticals, Inc. | Večvalentne soli piridostigmina in sorodnih spojin |
| US5925672A (en) | 1996-12-06 | 1999-07-20 | Neurosciences Research Foundation, Inc. | Methods of treating mental diseases, inflammation and pain |
| TW492882B (en) | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
| US7897598B2 (en) * | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
| US6251931B1 (en) * | 1998-11-24 | 2001-06-26 | The Scripps Research Institute | Inhibitors of gap junction communication |
| US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| US6359010B1 (en) * | 1999-11-23 | 2002-03-19 | Thomas D. Geracioti, Jr. | Methods of treating anxiety and mood disorders with oleamide |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| KR100613196B1 (ko) | 2000-07-19 | 2006-08-18 | 에프. 호프만-라 로슈 아게 | 메탈로프로테아제 억제제로서의 피롤리딘 유도체 |
| FR2812876B1 (fr) * | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| CZ2003451A3 (cs) | 2000-08-16 | 2003-10-15 | F. Hoffmann-La Roche Ag | Nové deriváty aminocyklohexanu |
| ATE348829T1 (de) | 2001-02-06 | 2007-01-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen |
| US6562846B2 (en) * | 2001-04-27 | 2003-05-13 | Bristol-Myers Squibb Company | Bisarylimidazolyl fatty acid amide hydrolase inhibitors |
| EP1458374A2 (en) | 2001-12-14 | 2004-09-22 | Novo Nordisk A/S | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| US6908939B2 (en) * | 2001-12-21 | 2005-06-21 | Galderma Research & Development S.N.C. | Biaromatic ligand activators of PPARγ receptors |
| US6949574B2 (en) * | 2002-02-08 | 2005-09-27 | Bristol-Myers Squibb Company | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| FR2843964B1 (fr) * | 2002-08-29 | 2004-10-01 | Sanofi Synthelabo | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique |
| EA010267B1 (ru) | 2002-10-07 | 2008-06-30 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Модуляция тревоги через блокаду гидролиза анандамида |
-
2003
- 2003-10-07 EA EA200500615A patent/EA010267B1/ru not_active IP Right Cessation
- 2003-10-07 CN CNB2003801052130A patent/CN100408556C/zh not_active Expired - Fee Related
- 2003-10-07 US US10/681,858 patent/US7176201B2/en not_active Expired - Lifetime
- 2003-10-07 CA CA2501506A patent/CA2501506C/en not_active Expired - Fee Related
- 2003-10-07 MX MXPA05003715A patent/MXPA05003715A/es unknown
- 2003-10-07 WO PCT/US2003/031844 patent/WO2004033422A2/en not_active Ceased
- 2003-10-07 EP EP03773201.3A patent/EP1558591B1/en not_active Expired - Lifetime
- 2003-10-07 JP JP2004543510A patent/JP4515911B2/ja not_active Expired - Fee Related
- 2003-10-07 AU AU2003279877A patent/AU2003279877B2/en not_active Ceased
- 2003-10-07 UA UAA200504339A patent/UA80841C2/xx unknown
- 2003-10-07 KR KR1020057005995A patent/KR20050088992A/ko not_active Ceased
-
2006
- 2006-07-28 US US11/496,051 patent/US8003693B2/en active Active
-
2011
- 2011-08-16 US US13/211,219 patent/US20120010283A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040127518A1 (en) | 2004-07-01 |
| EP1558591A4 (en) | 2007-09-12 |
| CA2501506C (en) | 2014-02-11 |
| KR20050088992A (ko) | 2005-09-07 |
| JP4515911B2 (ja) | 2010-08-04 |
| AU2003279877A1 (en) | 2004-05-04 |
| EP1558591A2 (en) | 2005-08-03 |
| US7176201B2 (en) | 2007-02-13 |
| US8003693B2 (en) | 2011-08-23 |
| JP2006511484A (ja) | 2006-04-06 |
| WO2004033422A2 (en) | 2004-04-22 |
| MXPA05003715A (es) | 2005-09-30 |
| US20090048337A1 (en) | 2009-02-19 |
| AU2003279877B2 (en) | 2010-05-20 |
| WO2004033422A3 (en) | 2004-07-29 |
| EA010267B1 (ru) | 2008-06-30 |
| CN100408556C (zh) | 2008-08-06 |
| EP1558591B1 (en) | 2014-05-07 |
| EA200500615A1 (ru) | 2005-10-27 |
| CA2501506A1 (en) | 2004-04-22 |
| US20120010283A1 (en) | 2012-01-12 |
| CN1729171A (zh) | 2006-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA80841C2 (en) | Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants) | |
| TW200519088A (en) | Aryl or heteroaryl amide compounds | |
| ES2141688A1 (es) | Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos. | |
| RU2006131132A (ru) | 1,3,5,-тризамещенные производные 4,5-дигидро-1н-пиразола, обладающие св1-антагонистической активностью | |
| BRPI0409949A (pt) | compostos de pirazol amida aril-substituìda úteis como inibidores de cinase | |
| EP0343900A3 (en) | Piperazine compounds | |
| SE0202134D0 (sv) | Therapeutic agents | |
| ATE383338T1 (de) | N-(phenyl(piperidin-2-yl)methyl)benzamid-deriva e,verfahren zu deren herstellung und ihre therapeutische verwendung | |
| EA200000327A2 (ru) | Новые соединения аминотриазола, способ их получения и содержащие их фармацевтические композиции | |
| WO2005092858A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist | |
| EP2423207A3 (en) | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | |
| DK1480961T3 (da) | Glutaminylbaserede DPIV-inhibitorer | |
| CA2497868A1 (en) | Heterocyclic compounds | |
| SE0104332D0 (sv) | Therapeutic agents | |
| RU2008111991A (ru) | Органические соединения | |
| EP1063228A4 (en) | CYCLOALCENE DERIVATIVES, THEIR MANUFACTURING METHOD AND THE USE THEREOF | |
| TW200510317A (en) | Caspase inhibitors and uses thereof | |
| UA49801C2 (uk) | Похідні тропан-2-альдоксиму, спосіб їх отримання, фармацевтична композиція, спосіб лікування | |
| WO2005056535A8 (en) | 1,2,3-triazole amide derivatives as inhibitors of cytokine production | |
| MA32978B1 (fr) | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique | |
| MY143245A (en) | 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases | |
| RU2004117531A (ru) | Использование производных 2-амино-4-пиридилметилтиазолина в качестве ингибиторов индуцибельной no-синтазы | |
| EA200200682A1 (ru) | Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие | |
| PE20040975A1 (es) | Derivados de aril- y heteroarilmorfolina | |
| EA200500716A1 (ru) | Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат |